Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 booster study of VLPCOV-01 in adults previously given 2 doses of BNT162b2
jRCT2051210164Phase 1Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VLPCOV-04 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by VLP Therapeutics Japan. Primary endpoints: Solicited reactogenicity adverse events, Unsolicited adverse events and 2 more. Started Feb 2022; status: completed.
02
Drugs
VLPCOV-04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210164.